Advanced Enzyme Q1 FY27 Results (NSE: ADVENZYMES)
Signal: Growth decelerated
The read
The quarter shows a fragile consolidated trajectory: revenue grew only 2.1% YoY to ₹189.79 Cr, EBITDA fell 2.0% to ₹63.99 Cr and PAT fell 7.1% to ₹37.09 Cr, while the standalone business deteriorated sharply with EBITDA down 61.2% and PAT down 69.8%; the 24.3% contribution of other income to PBT also reduces earnings quality.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹189.79 Cr | 2.1% | N/A |
| EBIT | ₹54.11 Cr | -2.8% | |
| Net profit | ₹37.09 Cr | -7.1% | |
| EPS | ₹3.31 | -7.3% | |
| EBIT margin | 33.7% |
P&L walk
Consolidated revenue rose 2.1% YoY to ₹189.79 Cr, but EBITDA declined 2.0% to ₹63.99 Cr and EBIT declined 2.8% to ₹54.11 Cr; PAT fell 7.1% to ₹37.09 Cr, with ₹13.02 Cr of other income contributing 24.3% of PBT.
Segments
There is no segment table, but the standalone-versus-consolidated split is material: standalone PAT fell 69.8% YoY to ₹22.35 Cr versus a 7.1% consolidated decline to ₹37.09 Cr, indicating subsidiaries materially cushioned the parent-level weakness.
Key positives
- Consolidated revenue increased 2.1% YoY to ₹189.79 Cr despite EBITDA declining 2.0%, showing that the group retained top-line growth.
- Consolidated EPS of ₹3.31 declined 7.3% YoY versus PAT decline of 7.1%, indicating no material EPS dilution signal.
- The company approved a buyback of up to ₹697,000,000, representing 9.99% of standalone and 5.09% of consolidated paid-up capital and free reserves, subject to the stated limits.
Key concerns
- Standalone revenue declined 7.3% YoY to ₹115.86 Cr, while standalone EBITDA fell 61.2% to ₹32.70 Cr and PAT fell 69.8% to ₹22.35 Cr.
- Consolidated EBITDA declined 2.0% YoY to ₹63.99 Cr despite revenue growth of 2.1%, indicating margin pressure with no operating driver disclosed in the filing.
- The group’s ₹13.02 Cr other income represented 24.3% of PBT, making the ₹37.09 Cr consolidated PAT less representative of recurring operating performance.
Earnings quality: includes non-operating other income
Research and educational content only. Not investment advice.